Professor Minghao Zheng, Orthocell’s Co-Founder and Chief Scientific Officer, has been elected as a Fellow of the Australian Academy of Health and Medical Sciences (AAHMS).
Orthocell Appoints Exclusive Remplirâ„¢ Distributor for Hong Kong
Orthocell has appointed medical device distributor MontsMed as its exclusive in-country distributor for Remplir in the key Asian market of Hong Kong.Â
Orthocell secures global distribution rights to innovative bone regeneration technology
Orthocell has signed Memorandum of Understanding to increase its equity stake in Marine Biomedical – from 1.7% to 12.0% for a total consideration of AU$1.0 million – securing exclusive first right of refusal over global distribution rights their groundbreaking bone substitute product, PearlBoneâ„¢.
$30.0 Million Placement to Accelerate Global Commercialisation and Advance Product Portfolio
Orthocell has today announced that it has received firm commitments for a $30 million capital raising via an institutional placement.
Quarterly Report – period ended 30 September 2025
Orthocell has today released its Quarterly Report for the period ended 30 September 2025, outlining a period of continued growth and strong commercial progress.
Orthocell Announces Record Revenue of $3m for September Quarter
Orthocell has announced record quarterly revenue of $3.0 million for the September quarter – our sixth consecutive quarter of record revenue growth.
Orthocell Appoints First Distributor for Remplirâ„¢ in US$75m Canadian Market
Orthocell has appointed its first Canadian distributor for Remplirâ„¢, signalling the commencement of the Company’s commercial roll out in the US$75m Canadian nerve repair market.Â
Global opportunity emerges as Remplirâ„¢ is used in nerve-sparing prostate cancer surgery
Orthocell has identified a promising new application for its flagship Remplirâ„¢ nerve repair device – for use in nerve-sparing Robotic-Assisted Radical Prostatectomies (RARP).
Remplirâ„¢ Real World Evidence study delivers compelling 81% success rate
Orthocell has today released interim results from a new Remplirâ„¢ Real World Evidence study, demonstrating an overall treatment success rate of 81.1% following nerve repair procedures.
Commercialisation of Remplirâ„¢ into US Market Continues to Build Momentum
Orthocell has today provided update on the continuing successful commercialisation of its flagship nerve repair product Remplirâ„¢ in the US.